Topics
Glenmark Pharmaceuticals | Diabetes drug
It has been launched under the brand name Zita-PioMet, and contains Teneligliptin (20 mg), Pioglitazone (15 mg) and Metformin (500mg/1000mg) in a sustained release (SR) formulation.
').insertAfter(".article-content__img");$(".article-content__img div").find('div').remove();
Glenmark Pharmaceuticals Ltd on Wednesday said it has launched triple fixed-dose combination Teneligliptin with Pioglitazone and Metformin in India for diabetic patients.
This fixed-dose combination offers patients with Type 2 diabetes the convenience of once daily dosing to improve their glycemic control. It is priced at Rs 14.90 per day, thereby reducing the daily cost of therapy by 40 per cent, making it more affordable to the masses, the company said in a statement.
It has been launched under the brand name Zita-PioMet, and contains Teneligliptin (20 mg), Pioglitazone (15 mg) and Metformin (500mg/1000mg) in a sustained release (SR) formulation, it added.
"Type 2 diabetes patients in India often face issues of beta cell dysfunction along with insulin resistance. In fact, the prevalence of high insulin resistance in India is 38 per cent compared to the global incidence of 15 per cent," Glenmark Pharmaceuticals EVP & Business Head - India Formulations Alok Malik said.
The market for oral anti-diabetic drugs in India is estimated to be Rs 11,877 crore with an annual growth of 6.3 per cent against the corresponding period previous year, the company said citing IQVIA sales data for the 12-month period ended November 2022.
It further said as per the International Diabetes Federation (IDF), the prevalence of diabetes in India is expected to increase to 125 million by 2045, 77 per cent of which would have uncontrolled diabetes.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Exclusive Stories, Curated Newsletters, 26 years of Archives, E-paper, and more!
First Published: Wed, December 21 2022. 23:32 IST
JPMorgan has deployed an AI-based research analyst chatbot to enhance productivity among its workforce, with approximate... Read more
Private equity has emerged as a significant force in the global financial landscape, driving substantial growth and inve... Read more
The world’s leading financial stability watchdog has issued a warning about the unresolved vulnerabilities within the ... Read more
In a week marked by strong financial performance, JPMorgan Chase & Co. reported a 25% rise in profits, and US small-... Read more
The financial industry is a competitive landscape where big banks and regional banks vie for market share. Each type of ... Read more
The landscape of philanthropic advisory services provided by private banks has undergone a significant transformation. T... Read more
